ArticleFrontiers in medicine2026
MAFLD is associated with lower bone mineral density in patients with type 2 diabetes: an exploratory cross-sectional analysis of a potential indirect association with HOMA-IR.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and bone mineral density (BMD) in patients with type 2 diabetes mellitus (T2DM), and to explore whether insulin resistance, as indicated by HOMA-IR, statistically accounts for part of this association. Methods: This retrospective cross-sectional study included 169 patients with T2DM, comprising 108 men with a mean age of 57.43 ± 11.98 years and 61 women with a mean age of 64.02 ± 13.19 years. Participants were divided according to MAFLD status into the MAFLD group ( Results: Compared to the non-MAFLD group, patients in the MAFLD group had significantly lower BMD T-scores (-1.12 ± 1.16 vs. -0.50 ± 1.07, Conclusion: In this exploratory single-center cross-sectional study of patients with T2DM, MAFLD was associated with lower BMD. The observed indirect effect via HOMA-IR was modest and should be interpreted as a cross-sectional statistical finding suggestive of a potential pathway; it does not establish temporal sequence, causality, or intervention utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.